Sanofi makes two new senior hires
pharmafile | August 2, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Sanofi
Sanofi has announced the appointments of Carsten Hellmann and David Meeker to its executive committee team.
Hellmann (pictured) joins Sanofi from biopharma firm Chr. Hansen Holding, and will take the position of executive vice president of Merial, its Animal Health division, following the decision by Jose Barella to leave the company to pursue other opportunities. He will be based in Lyon.
Meeker, currently chief executive of Genzyme and member of the Global Leadership Team, will join the committee as executive vice president, Genzyme.
Barella joined Merial in 2001 as head of the Companion Animals Franchise and eventually became executive chairman in 2007. He played a key role in the development of Merial over the years and its integration of the firm into the Sanofi family.
In his previous role, Hellmann was executive VP, Global Sales, Chr.Hansen Holding, a position he took up on joining the company in 2006.
Christopher Viehbacher, chief executive of Sanofi said: “Throughout his career, Carsten has gained an impressive reputation for building successful businesses. He has a wide and varied experience in life sciences, pharma and diagnostics.
“I am confident that with his expertise across the value chain from R&D, industrial affairs and through to business development and commercial sales, he will accelerate the growth of this promising division. I would like to thank Jose for his energy and commitment to the Group and wish him all the best in his future endeavours.”
On Meeker’s appointment Viehbacher added: “David’s leadership is testament to his talent and passion for patients. David has a deep knowledge of the rare diseases business and has developed a deep understanding of what physicians and patients need. David will be a valuable addition to the executive committee and I am pleased to welcome him on board.”
Related Content
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …
Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …
Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …
